SCHEMBL5025925

SCHEMBL5025925

COc1cccc(NC(=O)c2ccc(C)c(Nc3nc(-c4ccncc4)cs3)c2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.67
ALDH1A1 P00352 2/20 0.67
THRB P10828 1/20 0.67
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 1/20 0.55
CYP3A4 P08684 2/20 0.54
CLK1 P49759 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
PKM P14618 1/20 0.54
CYP2C19 P33261 1/20 0.54
GSK3A P49840 1/20 0.54
GSK3B P49841 1/20 0.54
CDK5 Q00535 1/20 0.54
CDK5R1 Q15078 1/20 0.54
ROCK1 Q13464 5/20 0.54
PRKACA P17612 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5027660 0.90 MAPT (0.62) MAPTALDH1A1THRBMEN1KMT2A
SCHEMBL5025066 0.90 MPL (0.56) MAPTALDH1A1THRBROCK1ABL1
SCHEMBL5025231 0.88 MEN1 (0.60) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL5025283 0.87 MAPT (0.62) MAPTALDH1A1THRBMEN1KMT2A
SCHEMBL5029449 0.87 MEN1 (0.62) MAPTALDH1A1THRBMEN1KMT2A
SCHEMBL5023715 0.87 ABL1 (0.60) MAPTALDH1A1THRBMEN1KMT2A
SCHEMBL5025243 0.86 ABL1 (0.59) MAPTALDH1A1THRBMEN1KMT2A
SCHEMBL5025279 0.86 ABL1 (0.53) MAPTALDH1A1THRBMEN1KMT2A
SCHEMBL4825391 0.85 ABL1 (0.66) MAPTALDH1A1THRBMEN1KMT2A
SCHEMBL5025070 0.85 ABL1 (0.53) MAPTALDH1A1THRBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US claimed
EP-1711497-A1 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS AB Science (FR) 2006-10-18 EP claimed
WO-2005073225-A1 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2005-08-11 WO claimed
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US disclosed
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US disclosed
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US disclosed
EP-1711497-A1 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS AB Science (FR) 2006-10-18 EP disclosed
WO-2005073225-A1 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors KIT, MAP3K2, RET MAPT 2933/4885ALDH1A1 1174/4885THRB 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.